Antenatal care in Nigeria forms the bedrock of maternal and child survival strategies. Preventing common, life-threatening conditions during pregnancy remains a core duty for midwives working at primary healthcare centres, mission clinics, and tertiary hospitals. Two foundational preventative interventions routinely delivered during antenatal clinic visits are tetanus immunization and malaria chemoprevention. Both measures target diseases that historically contribute heavily to maternal mortality and neonatal death across sub-Saharan Africa. Midwives must understand that these interventions are not merely routine paperwork, but active barriers protecting vulnerable mothers and their unborn infants from preventable infections.
Neonatal tetanus is a devastating, highly fatal disease caused by the neurotoxin produced by Clostridium tetani spores entering through unsterile umbilical cord cutting practices. Administering tetanus toxoid (TT) or tetanus and diphtheria (Td) vaccine to pregnant women stimulates active immunity, allowing maternal IgG antibodies to cross the placenta and protect the newborn during the first weeks of life. Midwives should reassure mothers that receiving this vaccine is completely safe for the fetus and does not cause congenital malformations, addressing a common community myth that modern injections harm unborn babies.
For administration, the midwife draws 0.5 ml of the vaccine into a sterile auto-disable syringe and injects it intramuscularly into the left upper arm deltoid muscle. Always inspect the vaccine vial monitor to confirm the vaccine potency before drawing the dose.
Malaria in pregnancy is a major public health emergency that causes maternal anaemia, placental sequestration, intrauterine growth restriction, low birth weight, and infant loss. To combat this, the World Health Organization and Nigerian national guidelines recommend Intermittent Preventive Treatment for Malaria using Sulfadoxine-Pyrimethamine (IPTp-SP). This intervention involves administering a full curative treatment course of SP at routine antenatal visits, regardless of whether the woman is currently infected with malaria parasites or not. It clears undetected parasites in the placenta and blood, significantly reducing adverse pregnancy outcomes.
IPTp-SP administration begins as soon as possible during the second trimester, specifically once quickening is felt, usually around 13 to 16 weeks of gestation. Midwives must administer SP as directly observed therapy (DOT) right inside the clinic, ensuring the woman swallows the tablets before leaving. Doses must be spaced at least one month apart until the time of delivery. A pregnant woman should receive a minimum of three doses during her pregnancy. Note that SP should not be given during the first trimester, and women taking daily co-trimoxazole prophylaxis for HIV must not receive SP concurrently to avoid severe toxicity.
Good clinical communication prevents default from antenatal preventive therapies. Some women experience mild nausea, dizziness, or localized skin itching after taking Sulfadoxine-Pyrimethamine, while others report minor arm soreness following a tetanus injection. Midwives must prepare clients for these normal reactions ahead of time. Advise mothers to take their SP tablets with water after a meal rather than on an empty stomach to minimize gastric irritation. Reassure them that cold compresses can relieve local injection site discomfort without needing harsh medications.
Accurate record-keeping is vital for continuity of care and public health auditing. Every dose of tetanus toxoid and IPTp-SP administered must be clearly recorded in the woman's antenatal card, the facility's maternal and child health register, and her personal immunization card. The midwife must write down the exact date, batch number where applicable, and the specific dose number (such as TT2 or IPTp 3). Failing to document these details often leads to missed doses or unnecessary repeat administrations, which compromises maternal safety.